search
Back to results

Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients

Primary Purpose

Ulcerative Colitis

Status
Unknown status
Phase
Phase 4
Locations
Lebanon
Study Type
Interventional
Intervention
Sodium Picosulfate/Magnesium Citrate Laxative
2L polyethylene glycol/ascorbic acid
Sponsored by
American University of Beirut Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Ulcerative Colitis

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients diagnosed with Ulcerative Colitis
  • Patients undergoing elective outpatient colonoscopy
  • Patients consenting to the study

Exclusion Criteria:

  • Age less than 18 years
  • Pregnant or lactating women
  • Significant gastroparesis
  • Gastric outlet obstruction
  • Ileus
  • Known or suspected bowel obstruction or perforation
  • Phenylketonuria
  • Toxic colitis or megacolon
  • Having a stoma
  • Compromised swallowing reflex or mental status
  • Psychiatric disease or known or suspected poor compliance
  • Severe chronic renal failure (creatinine clearance <30 mL/minute)
  • Severe congestive heart failure (New York Heart Association [NYHA] class III or IV)
  • Dehydration
  • Laxative use or dependency
  • Chronic constipation (<3 spontaneous bm/week)
  • Uncontrolled hypertension (systolic blood pressure ≥170 mm Hg, diastolic blood pressure ≥100 mm Hg)
  • Prior colon resection
  • Age above 65 years
  • Profusely bleeding patients with severe UC

Sites / Locations

  • American University of BeirutRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Citrafleet®

MoviPrep®

Arm Description

Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.

Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.

Outcomes

Primary Outcome Measures

Tolerability of the preparation as assessed by a Likert-type scale
Patients will answer a data collection sheet with questions regarding their ability to tolerate the preparation without difficulty. We are using a Likert-type scale from 1 to 5, 1 being completely intolerable and 5 being very easily tolerated.

Secondary Outcome Measures

Quality of the preparation as assessed by the Modified Aronchick scale.
A data collection sheet will be handed to the blinded endoscopist to answer questions related to the quality of the preparation. A description ranging from Poor to Excellent is assigned to the quality of the prepped colon. Poor - Re-preparation required; large amount of fecal residue precludes a complete examination Inadequate - Inadequate but examination completed; enough feces or turbid fluid to prevent a reliable examination; less than 90%mucosa seen Fair - Moderate amount of stool that can be cleared with suctioning permitting adequate evaluation of entire colonic mucosa; more than 90% mucosa seen Good - Small amount of turbid fluid without feces not interfering with examination; more than 90% mucosa seen Excellent - Small amount of clear liquid with clear mucosa seen; more than 95% mucosa seen
Quality of the preparation as assessed by the Boston Bowel Preparation Scale.
A data collection sheet will be handed to the blinded endoscopist to answer questions related to the quality of the preparation. A score ranging from 0 to 3 is assigned to each of the three segments of the colon: Right colon, Mid colon and Left colon. The scores are calculated as follows: 0 = Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared. = Portion of mucosa of the colon segment seen, but other areas of the colon segment not well seen due to staining, residual stool and/or opaque liquid. = Minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa of colon segment seen well. = Entire mucosa of colon segment seen well with no residual staining, small fragments of stool or opaque liquid.
Assessment of adherence to protocol
Patients will answer a set of questions in a data collection sheet pertaining to

Full Information

First Posted
March 27, 2018
Last Updated
September 18, 2019
Sponsor
American University of Beirut Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03581149
Brief Title
Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients
Official Title
Tolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene Glycol/Ascorbic Acid in Patients With Ulcerative Colitis Undergoing Colonoscopy: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 26, 2018 (Actual)
Primary Completion Date
July 26, 2020 (Anticipated)
Study Completion Date
July 26, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
American University of Beirut Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Ulcerative colitis is a chronic condition that results in the inflammation of the colon and rectum. Patients suspected to have ulcerative colitis are diagnosed via colonoscopy. Moreover, colonoscopy is considered to be the preferred procedure for assessing the activity and extent of the disease, as well as monitoring treatment response and development of lesions. Therefore, optimal performance and visualization of mucosal lesions via adequate bowel preparation is essential in such patients. In addition, the nature of the disease and the need for multiple colonoscopies throughout a patient's lifetime makes compliance to repeated procedures difficult. It is well known that colonoscopy preparations are generally poorly tolerated, disliked and, consequently serve as an additional burden on patients.Polyethylene glycol (PEG), despite being the golden standard, is not very well tolerated. Inadequate bowel preparations are associated with cancelled procedures, prolonged procedure time, incomplete examination, increased cost and possibly complications, physician frustration and patient anxiety, but most importantly, with missed pathology. A good bowel preparation would need a solution with reasonable volume, acceptable taste, minimal diet restrictions, and easy-to-follow instructions. The strict need for adherence to drinking a relatively large volume of solution preparation may result in poor compliance. Despite the emergence of several types of low volume preparations, the evidence on the use of such solutions remains sparse. This is especially true in terms of patients' tolerability to the solution, and its relation with adequate bowel preparation during colonoscopy. The investigator's aim is to assess how small volume preparations such as sodium picosulfate/magnesium citrate (Citrafleet®) enhance participants tolerability to the solution, compliance, and adequacy of bowel preparations when compared to 2L polyethylene glycol + ascorbic acid (MoviPrep®) in patients with Ulcerative Colitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ulcerative Colitis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
68 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Citrafleet®
Arm Type
Active Comparator
Arm Description
Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
Arm Title
MoviPrep®
Arm Type
Active Comparator
Arm Description
Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
Intervention Type
Drug
Intervention Name(s)
Sodium Picosulfate/Magnesium Citrate Laxative
Other Intervention Name(s)
(Citrafleet®)
Intervention Description
● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
Intervention Type
Drug
Intervention Name(s)
2L polyethylene glycol/ascorbic acid
Other Intervention Name(s)
(MoviPrep®)
Intervention Description
First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet. Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
Primary Outcome Measure Information:
Title
Tolerability of the preparation as assessed by a Likert-type scale
Description
Patients will answer a data collection sheet with questions regarding their ability to tolerate the preparation without difficulty. We are using a Likert-type scale from 1 to 5, 1 being completely intolerable and 5 being very easily tolerated.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Quality of the preparation as assessed by the Modified Aronchick scale.
Description
A data collection sheet will be handed to the blinded endoscopist to answer questions related to the quality of the preparation. A description ranging from Poor to Excellent is assigned to the quality of the prepped colon. Poor - Re-preparation required; large amount of fecal residue precludes a complete examination Inadequate - Inadequate but examination completed; enough feces or turbid fluid to prevent a reliable examination; less than 90%mucosa seen Fair - Moderate amount of stool that can be cleared with suctioning permitting adequate evaluation of entire colonic mucosa; more than 90% mucosa seen Good - Small amount of turbid fluid without feces not interfering with examination; more than 90% mucosa seen Excellent - Small amount of clear liquid with clear mucosa seen; more than 95% mucosa seen
Time Frame
1 year
Title
Quality of the preparation as assessed by the Boston Bowel Preparation Scale.
Description
A data collection sheet will be handed to the blinded endoscopist to answer questions related to the quality of the preparation. A score ranging from 0 to 3 is assigned to each of the three segments of the colon: Right colon, Mid colon and Left colon. The scores are calculated as follows: 0 = Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared. = Portion of mucosa of the colon segment seen, but other areas of the colon segment not well seen due to staining, residual stool and/or opaque liquid. = Minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa of colon segment seen well. = Entire mucosa of colon segment seen well with no residual staining, small fragments of stool or opaque liquid.
Time Frame
1 year
Title
Assessment of adherence to protocol
Description
Patients will answer a set of questions in a data collection sheet pertaining to
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with Ulcerative Colitis Patients undergoing elective outpatient colonoscopy Patients consenting to the study Exclusion Criteria: Age less than 18 years Pregnant or lactating women Significant gastroparesis Gastric outlet obstruction Ileus Known or suspected bowel obstruction or perforation Phenylketonuria Toxic colitis or megacolon Having a stoma Compromised swallowing reflex or mental status Psychiatric disease or known or suspected poor compliance Severe chronic renal failure (creatinine clearance <30 mL/minute) Severe congestive heart failure (New York Heart Association [NYHA] class III or IV) Dehydration Laxative use or dependency Chronic constipation (<3 spontaneous bm/week) Uncontrolled hypertension (systolic blood pressure ≥170 mm Hg, diastolic blood pressure ≥100 mm Hg) Prior colon resection Age above 65 years Profusely bleeding patients with severe UC
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ala Sharara, M.D
Phone
00961893989
Email
as08@aub.edu.lb
First Name & Middle Initial & Last Name or Official Title & Degree
Louma Rustam, M.D
Phone
00961952395
Email
lr22@aub.edu.lb
Facility Information:
Facility Name
American University of Beirut
City
Beirut
Country
Lebanon
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Louma Rustam, MD
First Name & Middle Initial & Last Name & Degree
Ala Sharara, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients

We'll reach out to this number within 24 hrs